CoChat

Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapy

Open access
Keir, Gregory J., Maher, Toby M., Hansell, David M., Denton, Christopher P., Ong, Voon H., Singh, Suveer, Wells, Athol U., Renzoni, Elisabetta A. · 2012 · European Respiratory Journal
Cited by 138

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

In very severe interstitial lung disease associated with connective tissue disease (CTD-ILD), progressing despite maximal conventional immunosuppression, there is no effective medical rescue therapy. The aim of the present study was to test whether rituximab, a monoclonal antibody that depletes peripheral B lymphocytes, is effective as rescue therapy in very severe CTD-ILD, unresponsive to conventional immunosuppression. We performed a retrospective assessment of eight patients with severe and progressive CTD-ILD treated with rituximab. In six patients, change in pulmonary function tests (PFTs) compared with pre-rituximab levels, was assessed at 9–12 months post-treatment. In two patients, who were mechanically ventilated at the time of treatment, clinical and HRCT changes were assessed. Seven out of eight patients had a favourable treatment response to rituximab, while in one patient disease severity did not change. In contrast with previous progression, we observed a median significant improvement of 22% in diffusing capacity for carbon monoxide (from a median baseline of 25%; range 16–32%; p=0.04), and a median significant improvement of 18% in forced vital capacity (from a median baseline of 45%; range 37–59%; p=0.03), in the 9–12 months following treatment with rituximab. In very severe CTD-ILD unresponsive to conventional immunosuppression, rituximab may represent an effective, potentially life-saving, therapeutic intervention.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1183/09031936.00163911

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 138

Metadata

Authors
Keir, G. J., Maher, T. M., Hansell, D. M., Denton, C. P., Ong, V. H., Singh, S., Wells, A. U., & Renzoni, E. A.
Venue
European Respiratory Journal
Published
2012-01-26
Volume
40
Issue
3
Pages
641-648
ISSN
  • 0903-1936 (ISSN-L)
  • 1399-3003
OpenAlex
W2105927222
Cited by
138
References
7
FWCI
11.15
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapy. https://app.cochat.ai/papers/10.1183/09031936.00163911
The paper
Keir, G. J., Maher, T. M., Hansell, D. M., Denton, C. P., Ong, V. H., Singh, S., Wells, A. U., & Renzoni, E. A. (2012). Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapy. European Respiratory Journal. https://doi.org/10.1183/09031936.00163911

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.